Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 306 of the 306 references it cites were found in a registry or an index.

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Open access

Abstract

Worldwide, nearly 40% of adults are overweight and 13% are obese. Health consequences of excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, and increased mortality. Treating obesity is challenging and calorie restriction often leads to rebound weight gain. Treatments such as bariatric surgery create hesitancy among patients due to their invasiveness. GLP-1 medications have revolutionized weight loss and can reduce body weight in obese patients by between 15% and 25% on average after about 1 year. Their mode of action is to mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism and satiety. However, GLP-1 drugs carry known risks and, since their use for weight loss is recent, may carry unforeseen risks as well. They carry a boxed warning for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) are fairly common while pancreatitis and intestinal obstruction are rarer. There may be a loss of lean body mass as well as premature facial aging. A significant disadvantage of using these medications is the high rate of weight regain when they are discontinued. Achieving success with pharmacologic treatment and then weaning to avoid future negative effects would be ideal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biom15030408

Cites

306 of 306 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Consequences of obesity-induced inflammation. Obesity leads to a physiological inflammatory response, such as oxidative stress, as illustrated by the hypertrophic adipocytes secreting pro-inflammatory cytokines, cardiometabolic conditions, and MALSD. These conditions increase the risk of mortality long-term which is generally associated with obesity.
Figure 1 Consequences of obesity-induced inflammation. Obesity leads to a physiological inflammatory response, such as oxidative stress, as illustrated by the hypertrophic adipocytes secreting pro-inflammatory cytokines, cardiometabolic conditions, and MALSD. These conditions increase the risk of mortality long-term which is generally associated with obesity.CC BY · PubMed Central
Figure 2 Adverse effects of GLP-1 class drugs. Gastrointestinal issues are common, ranging from nausea and diarrhea to rarer and more severe consequences such as pancreatitis. Rapid weight loss due to the use of GLP-1 drugs is associated with biliary disease, sarcopenia, and alopecia. Rapid weight loss can also lead to what is known as an “Ozempic face”, where the cheeks become hollowed out, and wrinkles, as well as eye bags, become more pronounced.
Figure 2 Adverse effects of GLP-1 class drugs. Gastrointestinal issues are common, ranging from nausea and diarrhea to rarer and more severe consequences such as pancreatitis. Rapid weight loss due to the use of GLP-1 drugs is associated with biliary disease, sarcopenia, and alopecia. Rapid weight loss can also lead to what is known as an “Ozempic face”, where the cheeks become hollowed out, and wrinkles, as well as eye bags, become more pronounced.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 304 references

Cited by

See all 66

Metadata

Authors
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J.
Affiliations
  • NYU Grossman Long Island School of Medicine (US)
  • Department of Medicine, NYU Grossman Long Island School of Medicine, Mineola, NY 11501, USA
Corresponding author
Reiss, Allison B.
Venue
Biomolecules
Publisher
MDPI AG
Published
2025-03-13
Volume
15
Issue
3
Pages
408
ISSN
2218-273X (ISSN-L)
OpenAlex
W4408387882
Cited by
58
References
304
Citations by year
2026: 41 · 2025: 17
FWCI
7.87
Type
journal article
Language
en
Open access
Locations
  • Biomolecules (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
GLP-1 receptor agonists, obesity, weight loss, weight regain, drug discontinuation, satiety, multiple endocrine neoplasia type 2, gastrointestinal adverse effects, pancreatitis, intestinal obstruction, lean mass loss, facial aging
MeSH terms
Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. https://app.cochat.ai/papers/10.3390/biom15030408
The paper
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025). Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss. Biomolecules. https://doi.org/10.3390/biom15030408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.